Stock Events

Stock Events

Mustang Bio 

$0.7399
110
+$0.06+8.84% 19:59 Today
+$0.01+1.37%23:17After hours

Statistics

Day High
0.7197
Day Low
0.7166
52W High
3.02
52W Low
0.531
Volume
1,074
Avg. Volume
-
Mkt Cap
5.61M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18AugExpected
Q2 2024
Q3 2024
Q4 2024
Q2 2025
Q3 2025
Q1 2026
Next
-6.5
-4.38
-2.26
-0.14
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-31.5MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MBIO. It's not an investment recommendation.
Microsoft
17
MSFT
NVIDIA
17
NVDA
Apple
16
AAPL
Amazon
14
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences, through its acquisition of Kite Pharma, is a leader in CAR-T therapy, directly competing in the same space as Mustang Bio.
Novartis
NVS
Mkt Cap305.1B
Novartis is a major player in CAR-T therapy with Kymriah, competing in the oncology space with Mustang Bio.
Precigen
PGEN
Mkt Cap2.01B
Precigen operates in the gene and cell therapy sector focusing on CAR-T and other cancer therapies, making it a direct competitor.
Sangamo Therapeutics
SGMO
Mkt Cap30.66M
Sangamo Therapeutics works on gene editing and gene therapy, competing with Mustang Bio in the development of genetic treatments for diseases.
CRISPR Therapeutics
CRSP
Mkt Cap5.92B
CRISPR Therapeutics is focused on gene editing technologies, including CRISPR/Cas9, which could compete with Mustang Bio's gene therapy approaches.
Allogene Therapeutics
ALLO
Mkt Cap717.92M
Allogene Therapeutics is focused on allogeneic CAR-T therapies for cancer, competing in the same space as Mustang Bio's autologous and allogeneic therapies.

About

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Show more...
CEO
Mr. Michael S. Weiss Esq., J.D.
Employees
4
Country
United States
ISIN
US62818Q3020

Listings

STU
DE
2W60.STU
XNAS
US
MBIO
BOATS
BOATS
MBIO.BOATS

0 Comments

Share your thoughts

FAQ

What is Mustang Bio stock price today?▼
The current price of MBIO is $0.74 USD — it has increased by +8.84% in the past 24 hours. Watch Mustang Bio stock price performance more closely on the chart.
What is Mustang Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Mustang Bio stocks are traded under the ticker MBIO.
Is Mustang Bio stock price growing?▼
MBIO stock has risen by +5.25% compared to the previous week, the month change is a -0.28% fall, over the last year Mustang Bio has showed a -76.21% decrease.
What is Mustang Bio market cap?▼
Today Mustang Bio has the market capitalization of 5.61M
When is the next Mustang Bio earnings date?▼
Mustang Bio is going to release the next earnings report on August 18, 2026.
What were Mustang Bio earnings last quarter?▼
MBIO earnings for the last quarter are -0.14 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Mustang Bio revenue for the last year?▼
Mustang Bio revenue for the last year amounts to 0 USD.
What is Mustang Bio net income for the last year?▼
MBIO net income for the last year is -31.5M USD.
How many employees does Mustang Bio have?▼
As of July 09, 2026, the company has 4 employees.
In which sector is Mustang Bio located?▼
Mustang Bio operates in the Health & Wellness sector.
When did Mustang Bio complete a stock split?▼
The last stock split for Mustang Bio was on January 16, 2025 with a ratio of 1:50.
Where is Mustang Bio headquartered?▼
Mustang Bio is headquartered in Waltham, United States.